Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genzyme hit on earnings surprise

GENZ was down $6.17 (24%) to $19.70 on 23.1 million shares on

Read the full 127 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE